Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis

Annals of Oncology

Volumn 20, Issue 12, 2009, Pages 2007-2012

  Delgado, J ^a   Pillai, S ^b   Phillips, N ^b   Brunet, S ^a   Pratt, G ^b   Briones, J ^a   Lovell, R ^b   Martino, R ^a   Ewing, J ^b   Sureda, A ^a   Milligan, D W ^b   Sierra, J ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Allogeneic HCT; Case control study; Chronic lymphocytic leukaemia

Indexed keywords

ALEMTUZUMAB; CD38 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN KINASE ZAP 70; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CASE CONTROL STUDY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; HUMAN CELL; LIVING DONOR; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SIBLING; SURVIVAL TIME;

EID: 70449502284     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp259     Document Type: Article

References (20)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
2. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008; 22: 211-219.
3. Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomized controlled trial. Lancet 2007; 370: 230-239.
4. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-1757.
5. Keating MJ, O'Brien S, Kontoyiannis D et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755-1762.
6. Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070-4078.
7. Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-2979.
8. Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study. Blood 2008; 111: 1094-1100.
9. Byrd JC, Lin TS, Dalton JT et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399-404.
10. Chanan-Khan A, Miller KC, Musial L et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 2006; 24: 5343-5349.
11. Sorror ML, Storer BE, Maloney DG et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111: 445-452.
12. Dreger P, Corradini P, Kimby E et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. Leukemia 2007; 21: 12-17.
13. Delgado J, Pillai S, Benjamin R et al. The effect of in vivo T-cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2008; 14: 1288-1297.
14. Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
15. H gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer 2006; 107: 1023-1033.
16. Dispenzieri A, Kyle RA, Lacy MQ et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: A case-control study. Blood 2004; 103: 3960-3963.
17. Dreger P, Stilgenbauer S, Benner A et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: A risk-matched analysis based on the VH gene mutational status. Blood 2004; 103: 2850-2858.
18. Delgado J, Thomson K, Russell N et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: A British Society of Blood and Marrow Transplantation Study. Blood 2006; 107: 1724-1730.
19. Brown JR, Kim HT, Li S et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2006; 12: 1056-1064.
20. Khouri IF, Saliba RM, Admirand J et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007; 137: 355-363.